Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21Waf1/Cip1

Robert H Weiss, Collette J. Randour

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Progressive fibrosis in major organs, including the heart, the kidney and the vascular tree, plays an important role in mediating chronic disease and atherosclerosis. Production of extracellular matrix proteins, in many cases regulated by the growth factor TGF-β is an essential component of this process. In a parallel manner to TGF-β, the cyclin kinase inhibitors (CKIs; which are induced by TGF-β) regulate transit through the cell cycle, and their effect on growth has been shown to be bimodal in the case of vascular smooth muscle (VSM) cells. Using an antisense oligodeoxynucleotide to the CKI p21Waf1/Cip1, developed in our laboratory and shown to specifically inhibit p21Waf1/Cip1 protein levels, we asked whether attenuation of the CKI p21Waf1/Cip1 by transfection of this oligodeoxynucleotide results in the abolition of TGF-β-mediated growth inhibition and/or diminished matrix protein production and secretion in the presence or absence of TGF-β. Specific inhibition of p21Waf1/Cip1 protein with the antisense oligodeoxynucleotide markedly reduces the production and secretion of the matrix proteins fibronectin and laminin, both in the presence and absence of TGF-β stimulation, in VSM cells as observed by Western blotting of cell lysate and conditioned medium. In addition, TGF-β-mediated cell growth inhibition, though attenuated by this oligo, is preserved. Due to the relative ease and safety of transfecting antisense oligodeoxynucleotides into VSM, we believe that this work unmasks a potentially powerful technique for inhibition of matrix protein synthesis in VSM and related cell lines, and may lead to new treatment strategies for atherosclerotic as well as other systemic diseases characterized by aberrant matrix protein secretion.

Original languageEnglish (US)
Pages (from-to)105-112
Number of pages8
JournalAtherosclerosis
Volume161
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Cyclins
Oligodeoxyribonucleotides
Phosphotransferases
Vascular Smooth Muscle
Smooth Muscle Myocytes
Proteins
Growth
Extracellular Matrix Proteins
Laminin
Conditioned Culture Medium
Fibronectins
Transfection
Blood Vessels
Atherosclerosis
Intercellular Signaling Peptides and Proteins
Cell Cycle
Fibrosis
Chronic Disease
Western Blotting
Kidney

Keywords

  • Atherosclerosis
  • Cyclin kinase inhibitor
  • Extracellular matrix
  • Vascular smooth muscle

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21Waf1/Cip1 . / Weiss, Robert H; Randour, Collette J.

In: Atherosclerosis, Vol. 161, No. 1, 2002, p. 105-112.

Research output: Contribution to journalArticle

@article{0905e5af08a345c9ae8c611e6e20871b,
title = "Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21Waf1/Cip1",
abstract = "Progressive fibrosis in major organs, including the heart, the kidney and the vascular tree, plays an important role in mediating chronic disease and atherosclerosis. Production of extracellular matrix proteins, in many cases regulated by the growth factor TGF-β is an essential component of this process. In a parallel manner to TGF-β, the cyclin kinase inhibitors (CKIs; which are induced by TGF-β) regulate transit through the cell cycle, and their effect on growth has been shown to be bimodal in the case of vascular smooth muscle (VSM) cells. Using an antisense oligodeoxynucleotide to the CKI p21Waf1/Cip1, developed in our laboratory and shown to specifically inhibit p21Waf1/Cip1 protein levels, we asked whether attenuation of the CKI p21Waf1/Cip1 by transfection of this oligodeoxynucleotide results in the abolition of TGF-β-mediated growth inhibition and/or diminished matrix protein production and secretion in the presence or absence of TGF-β. Specific inhibition of p21Waf1/Cip1 protein with the antisense oligodeoxynucleotide markedly reduces the production and secretion of the matrix proteins fibronectin and laminin, both in the presence and absence of TGF-β stimulation, in VSM cells as observed by Western blotting of cell lysate and conditioned medium. In addition, TGF-β-mediated cell growth inhibition, though attenuated by this oligo, is preserved. Due to the relative ease and safety of transfecting antisense oligodeoxynucleotides into VSM, we believe that this work unmasks a potentially powerful technique for inhibition of matrix protein synthesis in VSM and related cell lines, and may lead to new treatment strategies for atherosclerotic as well as other systemic diseases characterized by aberrant matrix protein secretion.",
keywords = "Atherosclerosis, Cyclin kinase inhibitor, Extracellular matrix, Vascular smooth muscle",
author = "Weiss, {Robert H} and Randour, {Collette J.}",
year = "2002",
doi = "10.1016/S0021-9150(01)00628-1",
language = "English (US)",
volume = "161",
pages = "105--112",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Attenuation of matrix protein secretion by antisense oligodeoxynucleotides to the cyclin kinase inhibitor p21Waf1/Cip1

AU - Weiss, Robert H

AU - Randour, Collette J.

PY - 2002

Y1 - 2002

N2 - Progressive fibrosis in major organs, including the heart, the kidney and the vascular tree, plays an important role in mediating chronic disease and atherosclerosis. Production of extracellular matrix proteins, in many cases regulated by the growth factor TGF-β is an essential component of this process. In a parallel manner to TGF-β, the cyclin kinase inhibitors (CKIs; which are induced by TGF-β) regulate transit through the cell cycle, and their effect on growth has been shown to be bimodal in the case of vascular smooth muscle (VSM) cells. Using an antisense oligodeoxynucleotide to the CKI p21Waf1/Cip1, developed in our laboratory and shown to specifically inhibit p21Waf1/Cip1 protein levels, we asked whether attenuation of the CKI p21Waf1/Cip1 by transfection of this oligodeoxynucleotide results in the abolition of TGF-β-mediated growth inhibition and/or diminished matrix protein production and secretion in the presence or absence of TGF-β. Specific inhibition of p21Waf1/Cip1 protein with the antisense oligodeoxynucleotide markedly reduces the production and secretion of the matrix proteins fibronectin and laminin, both in the presence and absence of TGF-β stimulation, in VSM cells as observed by Western blotting of cell lysate and conditioned medium. In addition, TGF-β-mediated cell growth inhibition, though attenuated by this oligo, is preserved. Due to the relative ease and safety of transfecting antisense oligodeoxynucleotides into VSM, we believe that this work unmasks a potentially powerful technique for inhibition of matrix protein synthesis in VSM and related cell lines, and may lead to new treatment strategies for atherosclerotic as well as other systemic diseases characterized by aberrant matrix protein secretion.

AB - Progressive fibrosis in major organs, including the heart, the kidney and the vascular tree, plays an important role in mediating chronic disease and atherosclerosis. Production of extracellular matrix proteins, in many cases regulated by the growth factor TGF-β is an essential component of this process. In a parallel manner to TGF-β, the cyclin kinase inhibitors (CKIs; which are induced by TGF-β) regulate transit through the cell cycle, and their effect on growth has been shown to be bimodal in the case of vascular smooth muscle (VSM) cells. Using an antisense oligodeoxynucleotide to the CKI p21Waf1/Cip1, developed in our laboratory and shown to specifically inhibit p21Waf1/Cip1 protein levels, we asked whether attenuation of the CKI p21Waf1/Cip1 by transfection of this oligodeoxynucleotide results in the abolition of TGF-β-mediated growth inhibition and/or diminished matrix protein production and secretion in the presence or absence of TGF-β. Specific inhibition of p21Waf1/Cip1 protein with the antisense oligodeoxynucleotide markedly reduces the production and secretion of the matrix proteins fibronectin and laminin, both in the presence and absence of TGF-β stimulation, in VSM cells as observed by Western blotting of cell lysate and conditioned medium. In addition, TGF-β-mediated cell growth inhibition, though attenuated by this oligo, is preserved. Due to the relative ease and safety of transfecting antisense oligodeoxynucleotides into VSM, we believe that this work unmasks a potentially powerful technique for inhibition of matrix protein synthesis in VSM and related cell lines, and may lead to new treatment strategies for atherosclerotic as well as other systemic diseases characterized by aberrant matrix protein secretion.

KW - Atherosclerosis

KW - Cyclin kinase inhibitor

KW - Extracellular matrix

KW - Vascular smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=0036191164&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036191164&partnerID=8YFLogxK

U2 - 10.1016/S0021-9150(01)00628-1

DO - 10.1016/S0021-9150(01)00628-1

M3 - Article

VL - 161

SP - 105

EP - 112

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 1

ER -